Park S, Jung JA, Ju S, Lim HS^†. Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab. Front Pharmacol. 2024 Jan 16;14:1288308.

Park SI, Kim S, Kim MG, Lim HS, Kim E. Modeling Approach with Therapeutic Drug Monitoring Data to Describe Time Course of Clozapine Exposure and PANSS Scores. Ther Drug Monit. Ther Drug Monit. 2023 Jun 1;45(3):417-424.

Lee MH, Yoon SK, Kim H, Cho YS, Han S, Lee SH, Bae KS, Jung J, Hong SH, Lim HS^†. Pharmacokinetic Interactions Between Bazedoxifene and Cholecalciferol: An Open-Label, Randomized, Crossover Study in Healthy Male Volunteers. Drug Des Devel Ther. 2023 Apr 12;17:1107-1114.

Han S, Choi HY, Kim YH, Choi S, Kim S, Nam JY, Kim B, Song GS, Lim HS, Bae KS. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut Liver. 2023 Jan 15;17(1):92-99.

Kim MJ, Kim H, Lee SM, Choi HY, Kim YH, Choi SC, Kim EH, Park HJ, Lim HS^†. Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2023 Jan;12(1):21-29.

Kim H, Lee SH, Jung J, Hong S, Lim HS^†. Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers. Drug Des Devel Ther. 2022 Feb 19;16:425-433

Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, Kim SK, Kim SJ, Kang YS, Kim TH, Mok J, Byun MK, Park HJ, Joh JS, Park YB, Lim HS, Choi H, Lee SH, Kim H, Yang J, Kim H, Shen X, Alsultan A, Cho I, Geiter L, Shim TS. Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0168421.

Cho YS, Bae KS, Choi SC, Cho JM, Lim HS^†. Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis. Clin Ther. 2022 Jan;44(1):67-80.

Jeong H, Hong YS, Kim JE, Lim HS, Ahn JB, Shin SJ, Park YS, Kim ST, Han SW, Kim TY, Kim TW. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2021 Oct;39(5):1335-1347.

Park SI, Kang DW, Lim HS^†. Modeling and simulation to predict the degree of disability over time in acute ischemic stroke patients. Clin Transl Sci. 2021 Sep;14(5):1988-1996.

Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, Lim HS, Bae KS. Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan. Clin Ther. 2021 Aug;43(8):1371-1380. 

Yu KS, Jang IJ, Lim HS, Hong JH, Kim MG, Park MK, Cho DY, Park MS, Chung JY, Ghim JL, Lee S, Yoon SK, Kwon IS, Lee SJ, Kim SH, Bae YJ, Cha JB, Furst DE, Keystone E, Kay J. Pharmacokinetic Equivalence of CT-P17 to High-Concentration (100 mg/mL) Reference Adalimumab: A Randomized Phase I Study in Healthy Subjects. Clin Transl Sci. 2021 Jul;14(4):1280-1291.

Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021 Jun;594(7863):418-423.

Han S, Cho YS, Yoon SK, Lim KS, Cho SH, Kim J, Choe S, Jung J, Ghim JL, Choi S, Lee M, Kim SM, Kim HT, Lim HS, Shim JY, Bae KS. First-in-human, double-blind, randomized controlled trial of an oral dose of GnRH antagonist, TU2670 in healthy women. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1111-e1120 

Han S, Kim YH, Choi HY, Soh DJ, Kim J, Nam J, Kim JW, Bae KS, Lim HS^†. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy Volunteers. Drug Des Devel Ther. 2020 Aug 5;14:3189-3199. 

Yoon SK, Bae KS, Hong DH, Kim SS, Choi YK, Lim HS^†. Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers. Drug Des Devel Ther. 2020 May 5;14:1729-1737.

Cui A, Kim YH, Ghim JL, Ah Jung J, Cho SH, Choe S, Choi HY, Bae KS, Lim HS^†. Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers. Xenobiotica. 2020 Mar;50(3):288-296.

Kim YM, Yum MS, Heo SH, Kim T, Jin HK, Bae JS, Seo GH, Oh A, Yoon HM, Lim HT, Kim HW, Ko TS, Lim HS, Osborn MJ, Tolar J, Cozma C, Rolfs A, Zimran A, Lee BH, Yoo HW. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet. 2020 Feb;57(2):124-131.

Yoon S, Bae KS, Cho YS, Han S, Kim H, Lim HS^†. Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer. J Clin Pharmacol. 2019 Nov; 59(11):1543-1550.

Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, Lim HS, Bae KS. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019 Oct;50(7):751-759.

Song IK, Yi S, Lim HS, Lee JH, Kim EH, Cho JY, Kim MC, Kim JT, Kim HS. A Population Pharmacokinetic Model of Intravenous Dexmedetomidine for Mechanically Ventilated Children after Neurosurgery. J Clin Med. 2019 Oct 1;8(10).

Han S, Kim YH, Choi HY, Kim MJ, Kim WJ, Park H, Bae KS, Lim HS^†. Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin. Pharm Res. 2019 Aug 8;36(10):146.

Bae DJ, Kim SY, Bae SM, Hwang AK, Pak KC, Yoon S, Lim HS^†. Whole body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics. J Pharm Sci. 2019 Jun;108(6):2180-2190.

Koh A, Pak KC, Choi HY, Ryu S, Choi SE, Kim KS, Bae KS, Lim HS^†. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. J Clin Pharmacol. 2019 Apr;59(4):532-540.

Park GC, Jung JA, Bae KS, Lim HS^†. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors. J Clin Pharmacol. 2017 Sep;57(9):1088-1096.

Ryu S, Park S, Lee JH, Kim YR, Na HS, Lim HS, Choi HY, Hwang IY, Lee JG, Park ZW, Oh WY, Kim JM, Choi SE. A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.

Ryu MH, Ryoo BY, Kim TW, Kim SB, Lim HS, Bae KS, Park SR, Jo YW, Cho HJ, Kang YK. A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. Oncologist. 2017 Feb;22(2):129-e8.

Choi HY, Choi S, Kim YH, Lim HS^†. Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers. CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):532-543.

Sung YS, Park B, Choi Y, Lim HS, Woo DC, Kim KW, Kim JK. Dynamic contrast-enhanced MRI for oncology drug development. J Magn Reson Imaging. 2016 Aug;44(2):251-64.

Cho SH, Lee JH, Lim HS, Lee KH, Kim DY, Choe S, Bae KS, Lee JH. Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation. Korean J Physiol Pharmacol. 2016 May;20(3):245-51.

Choi HY, Bae KS, Cho SH, Ghim JL, Choe S, Jung JA, Lim HS^†. Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in Korean healthy volunteers. Clin Pharmacol. 2016 Apr;56(4):439-49.

Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer. 2016 Apr;19(2):586-96

Jin SJ, Lim HS, Kwon YJ, Park SU, Yi JM, Chin JH, Hwang JH, Kim YK. Comparison of the Efficacy and Safety of a Pharmacokinetic Model-Based Dosing Scheme Versus a Conventional Fentanyl Dosing Regimen For Patient-Controlled Analgesia Immediately Following Robot-Assisted Laparoscopic Prostatectomy: A Randomized Clinical Trial. Medicine (Baltimore). 2016 Jan;95(2):e2542.

Choi HY, Bae KS, Cho SH, Ghim JL, Choe S, Jung JA, Jin SJ, Kim HS, Lim HS. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Pharmacogenet Genomics. 2015 Dec;25(12):595-608.

Choi HY, Kim YH, Hong D, Kim SS, Bae KS, Lim HS^†. Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers. Eur J Clin Pharmacol. 2015 Aug;71(8):967-77.

Lim HS^†, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim MJ, Park YI, Hwang A, Park SR. Post-Gastrectomy Pharmacokinetic Changes of S-1 in Patients with Localized Advanced Gastric Cancer. J Clin Pharmacol. 2015 Aug;55(8):926-35.

Kim YH, Ghim JL, Jung JA, Cho SH, Choe S, Choi HY, Bae KS, Lim HS^†. Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers. Drug Des Devel Ther. 2015 Jul 9;9:3571-7.

Kim YH, Choi HY, Noh YH, Lee SH, Lim HS, Kim C, Bae KS. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study. Drug Des Devel Ther. 2015 Jun 8;9:2911-8.

Lim HS, Bae KS. Modeling and simulation analysis of the relationship between lesion recurrence on brain images and clinical recurrence in patients with ischemic stroke. J Clin Pharmacol. 2015 Apr;55(4):458-66.

Kim YH, Choi HY, Lee SH, Lim HS, Miki T, Kang JK, Han KG, Bae KS. Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers. Drug Des Devel Ther. 2015 Mar 23;9:1735-42.

Kim YH, Choi HY, Lim HS, Lee SH, Jeon HS, Hong D, Kim SS, Choi YK, Bae KS. Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Des Devel Ther. 2015 Mar 10;9:1419-26.

HS Jeon, MJ Kim, HY Choi, YH Kim, EH Kim, AR Kim, HJ Park, KS Bae, HS Lim. Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Korean Male Volunteers. Clin Ther. 2015 Mar 1;37(3):563-73.

Kim YH, Choi HY, Lee SH, Jeon HS, Lim HS, Bahng MY, Bae KS. Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. Drug Des Devel Ther. 2015 Feb 23;9:1209-16.

Choi HY, Lim HS, Kim YH, Jeon HS, Kim MJ, Lee SH, Jung JH, Lee YK, Kim HJ, Bae KS. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41.

Lim HS, Bae KS, Jung JA, Noh YH, Hwang AK, Jo YW, Hong YS, Kim KP, Lee JL, Park SJ, Kim JE, Kang YK, Kim TW. Predicting the Efficacy of a Novel Oral Paclitaxel (DHP107) Through Modeling and Simulation. Clin Ther. 2015 Feb 1;37(2):402-17.

Kim YH, Choi HY, Jin S, Noh YH, Kim MJ, Park HJ, Lim HS, Bang K, Lee SH, Bae KS. Tolerability and Pharmacokinetics of Two Formulations of Megestrol Acetate under Fed Conditions in Healthy Volunteers. Clin Ther. 2015 Feb 1;37(2):439-47.

Noh YH, Lim HS, Jung JA, Song TH, Bae KS. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2015 Jan;75(1):97-109.

Kim MJ, Lim HS, Jin S, Jung JA, Noh YH, Kim YH, Bae KS. Pharmacokinetic, Pharmacodynamic, and Safety/Tolerability Profiles of CG100649, a Novel COX-2 Inhibitor: Results of a Phase I, Randomized, Multiple-Dose Study in Healthy Korean Men and Women. Clin Ther. 2015 Jan 1;37(1):197-210.

Choi HY, Kim YH, Kim MJ, Lee SH, Bang K, Han S, Lim HS, Bae KS. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs R D. 2014 Sep;14(3):165-76.

Jin SJ, Bae KS, Cho SH, Jung JA, Kim U, Choe S, Ghim JL, Noh YH, Park HJ, Kim HS, Lim HS. Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics. Pharm Res. 2014 Jul;31(7):1801-12.

Choi HY, Noh YH, Kim YH, Kim MJ, Lee SH, Kim JA, Kim B, Lim HS, Bae KS. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg × 2 tablets) fixeddose combination tablet in healthy male volunteers. Int J Clin Pharmacol Ther. 2014 May;52(5):381-91.

Lim HS, Chong YP, Noh YH, Jung JA, Kim YS. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation. J Clin Pharm Ther. 2014 Apr;39(2):196-203.

Choi HY, Kim YH, Kim MJ, Noh YH, Lee SH, Bae KS, Lim HS. Pharmacokinetics, Tolerability, and Safety of the Single Oral Administration of AGSAV301 vs Exforge: A Randomized Crossover Study of Healthy Male Volunteers. Am J Cardiovasc Drugs. 2014 Feb;14(1):63-72

Choi HY, Jin SJ, Jung JA, Kim UJ, Ko YJ, Noh YH, Bae KS, Lim HS. Effects of Ketoconazole on the Pharmacokinetic Properties of CG100649, A Novel NSAID: A Randomized, Open-Label Crossover Study in Healthy Korean Male Volunteers. Clin Ther. 2014 Jan 1;36(1):115-25.

Jung JA, Lim HS. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. Pharmacogenomics. 2014 Jan;15(1):49-60.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64.

Kim MJ, Lim HS, Noh YH, Kim YH, Choi HY, Park KM, Kim SE, Bae KS. Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: a randomized, open-label, crossover study of healthy Korean men. Clin Ther. 2013 Oct;35(10):1528-35.

Gwak HS, Lim HS, Shin SH, Yoo H, Han JY, Kim HT, Yun T, Lee JS, Lee SH. Ventriculolumbar Perfusion Chemotherapy for the Treatment of Leptomeningeal Carcinomatosis: A Phase I Study With Pharmacokinetic Data. Am J Clin Oncol. 2013 Oct;36(5):491-9.

Choi HY, Noh YH, Cho SH, Ghim JL, Choe S, Kim UJ, Ah Jung J, Bae KS, Lim HS. Evaluation of Pharmacokinetic and Pharmacodynamic Profiles and Tolerability After Single (2.5, 5, or 10 mg) and Repeated (2.5, 5, or 10 mg BID for 4.5 days) Oral Administration of Ivabradine in Healthy Male Korean Volunteers. Clin Ther. 2013 Jun;35(6):819-835.

Hong YS, Kim KP, Lim HS, Bae KS, Ryu MH, Lee JL, Chang HM, Kang YK, Kim H, Kim TW. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel. Invest New Drugs. 2013 Jun;31(3):616-22.

Lim HS, Kim SJ, Noh YH, Lee BC, Jin SJ, Park HS, Kim S, Jang IJ, Kim SE. Exploration of Optimal Dosing Regimens of Haloperidol, a D(2) Antagonist, via Modeling and Simulation Analysis in a D(2) Receptor Occupancy Study. Pharm Res. 2013 Mar;30(3):683-93.

Noh YH, Lim HS, Cho SH, Ghim JL, Choe S, Jung JA, Kim MJ, Kim YH, Jin SJ, Kim SB, Park JS, Lee SK, Yang WS, Chang JW, Lee B, Bae KS. Assessment of the influence of severe renal impairment on the pharmacokinetics of mirodenafil in Korean male volunteers. Int J Clin Pharmacol Ther. 2012 Dec;50(12):880-8.

Lee S, Chung JY, Hong KS, Yang SH, Byun SY, Lim HS, Shin SG, Jang IJ, Yu KS. Pharmacodynamic comparison of two formulations of Acarbose 100-mg tablets. J Clin Pharm Ther. 2012 Oct;37(5):553-7.

Choe S, Kim G, Lim HS, Cho SH, Ghim JL, Jung JA, Kim UJ, Noh G, Bae KS, Lee D. A simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patients. Korean J Physiol Pharmacol. 2012 Aug;16(4):273-80.

Choi HY, Noh YH, Jin SJ, Kim YH, Kim MJ, Sung H, Jang SB, Lee SJ, Bae KS, Lim HS. Bioavailability and Tolerability of Combination Treatment With Revaprazan 200 mg + Itopride 150 mg: A Randomized Crossover Study in Healthy Male Korean Volunteers. Clin Ther. 2012 Sep;34(9):1999-2010.

Noh YH, Lim HS, Jung JA, Jin SJ, Kim MJ, Kim YH, Park HJ, Bae KS. A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers. Int J Clin Pharmacol Ther. 2012 Aug;50(8):605-13.

Jin SJ, Jung JA, Cho SH, Kim UJ, Choe S, Ghim JL, Noh OH, Park HJ, Kim JC, Jung JA, Lim HS, Bae KS. The pharmacokinetics of letrozole - its association with key body mass metrics. Int J Clin Pharmacol Ther. 2012 Aug;50(8):557-65.

Noh YH, Lim HS, Kim MJ, Kim YH, Choi HY, Sung HR, Jin SJ, Lim J, Bae KS. Pharmacokinetic Interaction of Telmisartan With S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers. Clin Ther. 2012 Jul;34(7):1625-35

Noh YH, Lim HS, Jin SJ, Kim MJ, Kim YH, Sung HR, Choi HY, Bae KS. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug-Drug Interaction Study in Healthy Male Korean Volunteers. Clin Ther. 2012 May;34(5):1182-94.

Jung JA, Noh YH, Jin S, Kim MJ, Kim YH, Jung JA, Lim HS, Bae KS. Pharmacokinetic Interaction Between Pitavastatin and Valsartan: A Randomized, Open-Labeled Crossover Study in Healthy Male Korean Volunteers. Clin Ther. 2012 Apr;34(4):958-65.

Noh YH, Ko YJ, Cho SH, Ghim JL, Choe S, Jung JA, Kim UJ, Jin SJ, Park HJ, Song GS, Lim HS, Bae KS. Pharmacokinetic Comparison of 2 Formulations of Anastrozole (1 mg) in Healthy Korean Male Volunteers: A Randomized, Single-Dose, 2-Period, 2-Sequence, Crossover Study. Clin Ther. 2012 Feb;34(2):305-13.

Noh YH, Lim HS, Cho SH, Ghim JL, Choe S, Jung JA, Kim UJ, Park KM, Jang MJ, Bae KS. Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. Clin Ther. 2011 Sep;33(9):1132-41.

Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, Jung SY, Lee S. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat. 2011 Mar 25.

Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer. 2011 Feb 15;104(4):605-12.

Kim SD, Lee JH, Hur EH, Lee JH, Kim DY, Lim SN, Choi Y, Lim HS, Bae KS, Noh GJ, Yun SC, Han SB, Lee KH. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Aug;17(8):1222-30. 

Chung JY, Cho JY, Lim HS, Kim JR, Yu KS, Lim KS, Shin SG, Jang IJ. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos. 2011 Jan;39(1):92-7.

Jung J, Choi S, Cho SH, Ghim JL, Hwang A, Kim U, Kim BS, Koguchi A, Miyoshi S, Okabe H, Bae KS, Lim HS. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010 Jun;32(6):1178-87.

Kong SY, Lim HS, Nam BH, Kook MC, Kim YW, Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, Kim NK, Park SR. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics. 2009 Jul;10(7):1147-55.

Cho SH, Lim HS, Ghim JL, Choe S, Kim UJ, Jung JA, Bae KS. Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crossover study. Clin Ther. 2009 May;31(5):1046-53.

Lim HS, Im JS, Cho JY, Bae KS, TA. Klein, Yeom JS, Kim TS, Choi JS, Jang IJ, Park JW. Pharmacokinetics of hydroxychloroquine and its clinical implications in the chemoprophylaxis against vivax malaria. Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75.

Lee KS, Kim TH, Kim ES, Lim HS, Yeom JS, Jun G, Park JW. Short report: chloroquine-resistant Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg. 2009 Feb;80(2):215-7.

Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.

Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, Cho JY, Yu KS, Shin SG, Paick JS, Jang IJ. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008 Jun;65(6):848-54.

Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, Lee JS. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jan;59(1):69-75.

Lim HS, Lee HJ, Lee KS, Lee ES, Jang IJ, Ro JS. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007 Sep 1;25(25):3837-45.

Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007 Jul 1;110(1):138-47.

Lim HS, Cho JY, Oh DS, Chung JY, Hong KS, Bae KS, Yu KS, Lee KH, Jang IJ, Shin SG. Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II. Eur J Clin Pharmacol. 2007 Jan;63(1):17-26.

Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006 May 20;24(15):2237-44.

Han JY, Lim HS, Lee DH, Ju SY, Lee SY, Kim HY, Park YH, Park CG, Lee JS. Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Feb 15;106(4):873-80.

Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, Shin SG, Jang IJ. Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos. 2004 Dec;32(12):1341-4.

Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004 Aug;76(2):104-12.

Chun JH, Kim HK, Kim E, Kim IH, Kim JH, Chang HJ, Choi IJ, Lim HS, Kim IJ, Kang HC, Park JH, Bae JM, Park JG. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res. 2004 Jul 15;64(14):4703-6.

Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther. 2004 Nov;76(5):418-27.

Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol. 2004 Jan;44(1):73-82.

Cho JY, Lim HS, Yu KS, Shim HJ, Jang IJ, Shin SG. Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):179-86.

Kim MK, Cho JY, Lim HS, Hong KS, Chung JY, Bae KS, Oh DS, Shin SG, Lee SH, Lee DH, Min B, Jang IJ. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol. 2003 Jun;59(2):111-6.

Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, Jang IJ, Shin SG. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clin Pharmacol Ther. 2001 Sep;70(3):228-236.

Noh YH, Bae KS, Cho SH, Choe S, Ghim JL, Jung JA, Kim UJ, Jin SJ, Park HJ, Kim JC, Lim HS. Comparison of Pharmacokinetics and Safety of Two Formulations of Letrozole (2.5 mg) in Healthy Male Volunteers. J Korean Soc Clin Pharmacol Ther. 2012;20(2):135-144.

Kim S, Lee S, Lim KS, Lim HS, Shin SG, Jang IJ, Yu KS. Tolerability and Pharmacokinetics Following a Single Dose of Vardenafil in Healthy Korean Volunteers. J Korean Soc Clin Pharmacol Ther. 2012;20(2):125-134.

Choi HY, Kim JW, Lim HS, Cho SH, Ghim JL, Choe S, Jung JA, Lim J, Bae KS. Comparison of Pharmacokinetic Characteristics and the Safety between Amlodipine Maleate Tablet 5 mg and Amlodipine Besylate Tablet 5 mg. J Korean Soc Clin Pharmacol Ther. 2012;20(1):42-50.

Noh YH, Ko YJ, Jung JA, Kim UJ, Jin SJ, Hwang AK, Park HJ, Bae KS, Lim HS^†. Population Pharmacokinetic Analysis of Anastrozole in Healthy Korean male Volunteers. J Korean Soc Clin Pharmacol Ther. 2010 ;18(1):164-173.

Yi SY, Jang IJ, Bae KS, Cho JY, Yu KS, Lim HS, Chung JY, Hong KS, Bang YJ, Shin SG. Pharmacokinetic / Pharmacodynamic Model for the Time Course of Myelosuppression of New Anticancer Drug (CKD-602). J Korean Soc Clin Pharmacol Ther. 2004;12(1):16-26.

Chung JY, Lim HS, Hong KS, Bae KS, Yu KS, Cho JY, Yi SY, Ko JW, Jang IJ, Shin SG. Evaluation of Safety and Pharmacokinetics of Tegaserod After Multiple Oral Administrations in Healthy Korean Subjects. J Korean Soc Clin Pharmacol Ther. 2003;11(2):128-136.

Bae KS, Jang IJ, Lim HS, Lee KH, Yim DS, Shin SG. Study On The Age-Related Changes In The Activities Of Drug Metabolizing Enzymes: Cyp2D6 And N-Acetyltransferase. J Korean Soc Clin Pharmacol Ther. 2002;10(2):153-164.

Hong KS, Bae KS, Lim HS, Chung JY, Kim MK, Baik JM, Kang KJ, Park GJ, Jang IJ, Shin SG. Validation of the Assay for the Glucose of Human Venous Blood Using a Handy Blood Sugar Measuring Instrument. J Korean Soc Clin Pharmacol Ther. 2002;10(1):34-49.

Chung JY, Lim HS, Bae KS, Yu KS, Hong KS, Cho JY, Yi SY, Shin SG. Evaluation of Safety, Tolerability and Pharmacokinetics of Lebecel® (DDB-S); a Phase I Clinical Trial. J Korean Soc Clin Pharmacol Ther. 2001;9(2):188-196.

Lim HS^†, Hong KS, Chung JY, Yi SY, Bae KS, Kim MK, Cho JY, Jang IJ. Analysis of Dose-Titration Trial for Barnidipine with Nonlinear Mixed Effect Modeling and naive Pooled Data Method. J Korean Soc Clin Pharmacol Ther. 2001;9(2):174-187.

Lim HS^†, Yi SY, Cho JY, Bae KS, Yu KS, Jang IJ, Shin SG. Bioequivalence Study of Two Terazosin Formulations: TZC® Tablet and Hytrin® Tablet. J Korean Soc Clin Pharmacol Ther. 2001;9(1)57-65.

Yi SY, Bae KS, Lim HS, Cho JY, Yu KS, Park SS, Jang IJ, Shin SG. Population PK-PD modeling of Captopril in healthy volunteers. J Korean Soc Clin Pharmacol Ther. 2001;9(1):37-47.

Lim HS, Yi SY, Cho JY, Bae KS, Yu KS, Yim DS, Jang IJ, Shin SG. Pharmacokinetic Comparison of Two Formulations Containing Silymarin: Legalon cap. 140® vs. a Generic Formulation. J Korean Soc Clin Pharmacol Ther. 2001;9(1):19-25.